Literature DB >> 15292708

Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives.

Juan Antonio Marchal1, Houria Boulaiz, Inés Suárez, Estrella Saniger, Joaquín Campos, Esmeralda Carrillo, José Prados, Miguel Angel Gallo, Antonio Espinosa, Antonia Aránega.   

Abstract

In this study we evaluate the antitumour activity, the cell cycle arrest and apoptotic properties of novel lipophilic benzene-fused seven-membered 5-fluorouracil (5-FU) analogs in comparison to 5-FU on MCF-7 human breast cancer cells. The lipophilicities of ESB-786B, ESB-252A and ESB-928A were predicted by using the CDR option of the PALLAS 2.0 program. Cytotoxic assays were evaluated in MCF-7 cells treated with the sulforhodamine B colorimetric method. Cell cycle perturbations were studied by flow cytometry. Apoptosis was determined by both DNA fragmentation and annexin V-FITC and propidium iodide staining. The novel derivatives were more lipophilic than 5-FU and induced a marked growth inhibition, in a dose-dependent manner. After treatment with IC(50) value (ranged from 2.5 to 22 microM) for each compound, light microscopy observation showed modifications in the morphology of MCF-7 cells. In addition, the 5-FU analogs arrest cells in the G(0)/G(1) phase of the cell cycle whereas 5-FU induced arrest in S-phase. Moreover, induction of apoptosis was demonstrated by the annexin-V-based assay and confirmed using DNA fragmentation analysis on MCF-7 cells, a cell line in which the induction of DNA laddering is very difficult. The novel benzannelated seven-membered 5-FU analogs can be considered as specific apoptotic inducers. These experimental findings provide support for the use of these novel compounds as new weapons in the fight against breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292708     DOI: 10.1023/B:DRUG.0000036680.52016.5f

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  30 in total

Review 1.  Discovering novel chemotherapeutic drugs for the third millennium.

Authors:  M D Garrett; P Workman
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

2.  Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells.

Authors:  A Chadderton; D J Villeneuve; S Gluck; A F Kirwan-Rhude; B R Gannon; D E Blais; A M Parissenti
Journal:  Breast Cancer Res Treat       Date:  2000-02       Impact factor: 4.872

3.  Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells.

Authors:  P Maloof; Q Wang; H Wang; D Stein; T N Denny; J Yahalom; E Fenig; R Wieder
Journal:  Breast Cancer Res Treat       Date:  1999-07       Impact factor: 4.872

Review 4.  New options for outpatient chemotherapy--the role of oral fluoropyrimidines.

Authors:  D Cunningham; R Coleman
Journal:  Cancer Treat Rev       Date:  2001-08       Impact factor: 12.111

Review 5.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

6.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

7.  Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives.

Authors:  José F Domínguez; Juan A Marchal; Antonio Correa; Esmeralda Carrillo; Houria Boulaiz; Antonia Aránega; Miguel A Gallo; Antonio Espinosa
Journal:  Bioorg Med Chem       Date:  2003-02-06       Impact factor: 3.641

8.  The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation.

Authors:  R Sharma; E Adam; U Schumacher
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells.

Authors:  J A Marchal; J Prados; C Melguizo; J A Gómez; J Campos; M A Gallo; A Espinosa; N Arena; A Aránega
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602).

Authors:  J A Marchal; C Melguizo; J Prados; A E Aránega; J A Gómez; J Campos; M A Gallo; A Espinosa; N Arena; A Aránega
Journal:  Jpn J Cancer Res       Date:  2000-09
View more
  11 in total

1.  Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis.

Authors:  Fran Supek; Marijeta Kralj; Marko Marjanović; Lidija Suman; Tomislav Smuc; Irena Krizmanić; Biserka Zinić
Journal:  Invest New Drugs       Date:  2007-09-27       Impact factor: 3.850

2.  Anti-Cancerous Potential of Polysaccharides Derived from Wheat Cell Culture.

Authors:  Alima Murtazina; Gloria Ruiz Alcala; Yaiza Jimenez-Martinez; Juan Antonio Marchal; Anel Tarabayeva; Elmira Bitanova; Gordon McDougall; Nazira Bishimbayeva; Houria Boulaiz
Journal:  Pharmaceutics       Date:  2022-05-20       Impact factor: 6.525

3.  Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.

Authors:  Lekha Nair K; Sankar Jagadeeshan; S Asha Nair; G S Vinod Kumar
Journal:  Int J Nanomedicine       Date:  2011-08-17

4.  Cadmium influences the 5-Fluorouracil cytotoxic effects on breast cancer cells.

Authors:  Y Asara; J A Marchal; P Bandiera; V Mazzarello; L G Delogu; M A Sotgiu; A Montella; R Madeddu
Journal:  Eur J Histochem       Date:  2012-01-20       Impact factor: 3.188

5.  Biogenesis of ZnO nanoparticles using Pandanus odorifer leaf extract: anticancer and antimicrobial activities.

Authors:  Afzal Hussain; Mohammad Oves; Mohamed F Alajmi; Iqbal Hussain; Samira Amir; Jahangeer Ahmed; Md Tabish Rehman; Hesham R El-Seedi; Imran Ali
Journal:  RSC Adv       Date:  2019-05-16       Impact factor: 4.036

6.  Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.

Authors:  Kazuaki Matsuoka; Fumio Nakagawa; Takashi Kobunai; Teiji Takechi
Journal:  Oncotarget       Date:  2018-02-05

7.  Enhancement of Tumor Cell Death by Combining gef Gene Mediated Therapy and New 1,4-Benzoxazepin-2,6-Dichloropurine Derivatives in Breast Cancer Cells.

Authors:  Alberto Ramírez; Ana Conejo-García; Carmen Griñán-Lisón; Luisa C López-Cara; Gema Jiménez; Joaquín M Campos; Juan A Marchal; Houria Boulaiz
Journal:  Front Pharmacol       Date:  2018-07-26       Impact factor: 5.810

8.  A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.

Authors:  Yesenia L Franco; Vidya Ramakrishnan; Tanaya R Vaidya; Hardik Mody; Luis Perez; Sihem Ait-Oudhia
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-03       Impact factor: 2.745

9.  Cadmium modifies the cell cycle and apoptotic profiles of human breast cancer cells treated with 5-fluorouracil.

Authors:  Yolande Asara; Juan A Marchal; Esther Carrasco; Houria Boulaiz; Giuliana Solinas; Pasquale Bandiera; Maria A Garcia; Cristiano Farace; Andrea Montella; Roberto Madeddu
Journal:  Int J Mol Sci       Date:  2013-08-12       Impact factor: 5.923

10.  HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound.

Authors:  Alberto Ramírez; Houria Boulaiz; Cynthia Morata-Tarifa; Macarena Perán; Gema Jiménez; Manuel Picon-Ruiz; Ahmad Agil; Olga Cruz-López; Ana Conejo-García; Joaquín M Campos; Ana Sánchez; María A García; Juan A Marchal
Journal:  Oncotarget       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.